A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML

Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs JNJ 63709178 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 20 Jul 2017 Planned End Date changed from 27 Oct 2020 to 1 Oct 2020.
    • 10 Jun 2017 Biomarkers information updated
    • 26 Apr 2017 Planned End Date changed from 17 Apr 2019 to 27 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top